A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs ALT 803 (Primary) ; ALT 803 (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 31 Oct 2017 Planned End Date changed from 1 Jul 2018 to 1 Feb 2018.
- 31 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2017.
- 23 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.